Co-ordinated Drug Development Limited
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Co-ordinated Drug Development Limited - overview
Established
1983
Location
Bath, England, UK
Primary Industry
Pharmaceuticals
About
Co-ordinated Drug Development Limited is based in the UK and operates as a Pharmaceutical company.
Current Investors
Vectura Group Plc
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development
Company Stage
Add-on
Total Amount Raised
Subscriber access only
Co-ordinated Drug Development Limited - financials
| Fiscal Year Ended | Mar 31, 2010 | Mar 31, 2011 | Mar 31, 2012 | Mar 31, 2013 | Mar 31, 2014 | Mar 31, 2015 | Mar 31, 2016 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 13,900,000 | 17,200,000 | 12,666,000 | 16,448,000 | 15,900,000 | 31,500,000 | 46,400,000 | 26,900,000 | 19,200,000 | 22,600,000 | 25,000,000 | 38,600,000 | 35,900,000 | - | - | - |
| % Revenue Growth (YoY) | - | 23.7% | (26.4%) | 29.9% | (3.3%) | 98.1% | 47.3% | - | - | 17.7% | 10.6% | 54.4% | (7.0%) | - | - | - |
| EBITDA (USD) | (10,100,000) | (13,700,000) | (15,195,000) | (11,394,000) | (8,100,000) | (1,600,000) | 6,900,000 | (12,000,000) | (28,600,000) | (28,200,000) | (12,700,000) | 127,600,000 | (3,800,000) | - | - | - |
| Operating Income (USD) | (11,000,000) | (14,800,000) | (16,125,000) | (12,372,000) | (9,100,000) | (2,500,000) | 5,700,000 | (12,900,000) | (29,800,000) | (29,500,000) | (14,200,000) | 126,000,000 | (6,500,000) | - | - | - |
| Operating Margin | (79.1%) | (86.0%) | (127.3%) | (75.2%) | (57.2%) | (7.9%) | 12.3% | (48.0%) | (155.2%) | (130.5%) | (56.8%) | 326.4% | (18.1%) | - | - | - |
| % EBITDA Margin | (72.7%) | (79.7%) | (120.0%) | (69.3%) | (50.9%) | (5.1%) | 14.9% | (44.6%) | (149.0%) | (124.8%) | (50.8%) | 330.6% | (10.6%) | - | - | - |
| NET Income (USD) | (4,700,000) | (12,200,000) | (10,662,000) | (7,636,000) | (5,700,000) | (800,000) | 8,100,000 | (29,900,000) | (34,000,000) | (10,200,000) | (16,200,000) | 108,000,000 | (8,800,000) | - | - | - |
| % Net Margin | (33.8%) | (70.9%) | (84.2%) | (46.4%) | (35.8%) | (2.5%) | 17.5% | (111.2%) | (177.1%) | (45.1%) | (64.8%) | 279.8% | (24.5%) | - | - | - |
Co-ordinated Drug Development Limited - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on | Completed | Co-ordinated Drug Development Limited | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.